Waldencast Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on November 24, 2025, by Waldencast Plc, a foreign private issuer, reports on the six-month interim period ended June 30, 2025 (H1 2025). The filing incorporates the Unaudited Interim Consolidated Financial Statements for this period as Exhibit 99.1.
Key Financial Metrics
The provided text serves as a cover document and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced Exhibit 99.1, which is not included in the input text.
Material Changes and Recent Agreements
While financial comparisons are not detailed in the text, the filing discloses significant corporate agreements executed in November 2025:
- Credit Agreement: Dated November 14, 2025, involving Milk Makeup LLC, Obagi Cosmeceuticals LLC, and Waldencast Partners plc as the parent guarantor, with LSSF II Offshore Investments, LP as the administrative agent.
- Trademark Agreements: Dated November 13, 2025, between Rohto Pharmaceutical Co., Ltd. and Obagi Cosmeceuticals LLC, including a Trademark Transfer Agreement and a Trademark Coexistence Agreement.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors. It notes that the report is incorporated by reference into registration statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Review Exhibit 99.1 for the actual H1 2025 revenue, net income, and cash flow figures.
- Verify the terms and covenants of the new Credit Agreement dated November 14, 2025.
- Examine the scope of the trademark transfer and coexistence agreements with Rohto Pharmaceutical Co., Ltd.
- Confirm the impact of these November 2025 agreements on the company's liquidity and future operations.